Replies to post #32021 on Ocata Therapeutics Inc fka OCAT

[rumit]

Short answer, share count.

Almost 1.75 billion shares outstanding x .20 = $350 million market cap.

Using the issued share count the market cap is still around $300 million.

GERN is worth ~$600M
BTX is worth $230M
ASTM is worth $110M

Etc.

Say there was a split 25:1, shares outstanding is in the 70MM range, the PPS would be $5.00. This is more in line with the other companies here.

Market caps can be compared, PPS comparisons across companies are largely meaningless.

As far as risk reward, everyone has their own decisions to make.

Disclosure: Long ACTC

[johan31]

Short answer.....no products or proven therapies on the market. Of course that will all change if we get positive results from the trials. The share count does impede movement in the pps, but the share count will not keep it from going to .50 to .75 if we have preliminary positive results. At that point, if we can secure a JV, we easily break a buck IMHO...